ĐÁNH GIÁ THỜI GIAN SỐNG THÊM KHÔNG BỆNH TRÊN BỆNH NHÂN UNG THƯ DẠ DÀY ĐƯỢC HÓA TRỊ BỔ TRỢ PHÁC ĐỒ CAPOX TẠI BỆNH VIỆN HỮU NGHỊ VIỆT ĐỨC

Abstract

Objective: To evaluate disease free survival in patient treated with CAPOX regimen for gastric cancer at Viet Duc Friendship Hospital. Subjects and methods: A descriptive study with longitudinal follow-up of 65 patients with stage IB-III gastric cancer who underwent radical surgery and received chemotherapy with CAPOX regimen at Viet Duc Hospital. Results: The average age of patients was 58.3 years, the group over 60 years old accounted for 50.7%, 6.2% of patients were under 40 years old (4/65). Male patients accounted for 75.4%. Tumors in the pyloric antrum were 78.5%. Patients in stage IIIB accounted for the highest proportion (23.1%), stage IIB (21.5%) and IIIA (20.0%). 78.5% of patients underwent gastrectomy; 58.5% of patients underwent extended D2 lymphadenectomy. 69.2% of patients received adjuvant chemotherapy 4-6 weeks after surgery. The mean disease-free survival was 49.4 ± 3.2 months. The 3-year and 5-year disease-free survival rates were 66.2% and 47.7%, respectively. The 5-year disease-free survival rate in the moderately differentiated adenocarcinoma group (70.2%) was statistically significantly higher than that in the poorly differentiated (44.8%) and signet ring cell (41.1%) cancer groups. The 5-year disease-free survival rate in the group without neurovascular invasion was statistically significantly higher than that in the group with neurovascular invasion (p=0.002); The difference in disease-free survival between disease stages according to TMN classification was statistically significant; specifically, as the disease stage progressed, the 5-year survival rate decreased (p<0.001). Conclusion: The CAPOX adjuvant chemotherapy regimen showed effectiveness in patients with gastric cancer who had undergone radical surgery, especially patients with stage II and III disease.